keyword
MENU ▼
Read by QxMD icon Read
search

Fecal calprotectin

keyword
https://www.readbyqxmd.com/read/28539226/fecal-calprotectin-as-an-alternative-to-ulcerative-colitis-endoscopic-index-of-severity-to-predict-the-response-to-corticosteroids-of-acute-severe-ulcerative-colitis-a-prospective-observational-study
#1
Tingbin Xie, Chenyan Zhao, Chao Ding, Tenghui Zhang, Xujie Dai, Tengfei Lv, Yi Li, Zhen Guo, Jianfeng Gong, Weiming Zhu
BACKGROUND: Fecal calprotectin (FC) might be an alternative to ulcerative colitis endoscopic index of severity (UCEIS) to predict the response to corticosteroids (CS) in acute severe colitis (ASC). METHODS: One hundred and seventeen ASC patients were prospectively enrolled. Demographic, clinical, laboratory and sigmoidoscopic data were documented. Multivariate and ROC analyses were performed to identify risk factors for non-response to CS, and the predictive accuracy of possible predictors was assessed...
May 3, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28533922/correlation-of-rapid-point-of-care-vs-send-out-fecal-calprotectin-monitoring-in-pediatric-inflammatory-bowel-disease
#2
Alexis Rodriguez, Lauren Yokomizo, Megan Christofferson, Danielle Barnes, Nasim Khavari, K T Park
AIM: To assess the correlation between the send-out enzyme-linked immuno sorbent assay (ELISA) and the point-of-care (POC) calprotectin test in pediatric inflammatory bowel disease (IBD) patients. METHODS: We prospectively collected stool samples in pediatric IBD patients for concomitant send-out ELISA analysis and POC calprotectin testing using the Quantum Blue(®) (QB) Extended immunoassay. Continuous results between 17 to 1000 μg/g were considered for comparison...
May 6, 2017: World Journal of Gastrointestinal Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28528364/a-randomized-double-blind-placebo-controlled-trial-of-a-multi-strain-probiotic-in-treatment-of-symptomatic-uncomplicated-diverticular-disease
#3
Charlotte L Kvasnovsky, Ingvar Bjarnason, Ana Nora Donaldson, Roy A Sherwood, Savvas Papagrigoriadis
BACKGROUND: Diverticular disease is a significant burden on healthcare systems that is managed, surgically or medically, mainly as an emergency or acute condition. There are no standardized treatment recommendations for symptomatic uncomplicated disease. We hypothesized that a probiotic would reduce abdominal pain in such patients. METHODS: We conducted a single-center, double-blind, placebo-controlled trial of probiotic treatment (Symprove) in adult patients with moderate-to-severe chronic, non-acute symptomatic diverticular disease...
May 20, 2017: Inflammopharmacology
https://www.readbyqxmd.com/read/28523450/a-review-of-the-clinical-pharmacokinetics-pharmacodynamics-and-immunogenicity-of-vedolizumab
#4
REVIEW
Maria Rosario, Nathanael L Dirks, Catherine Milch, Asit Parikh, Michael Bargfrede, Tim Wyant, Eric Fedyk, Irving Fox
Vedolizumab is a humanized anti-α4β7 integrin monoclonal antibody that selectively blocks trafficking of memory T cells to inflamed gut tissue by inhibiting the α4β7-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) interaction. Approved for treating patients with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD), vedolizumab is administered as a 300 mg intravenous infusion. Vedolizumab undergoes a rapid, saturable, non-linear, target-mediated elimination process at low concentrations and a slower, linear, non-specific elimination process at higher concentrations...
May 18, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28520581/reply-to-accuracy-of-consecutive-fecal-calprotectin-measurements-to-predict-relapse-in-inflammatory-bowel-disease-patients
#5
Rocio Ferreiro-Iglesias, Manuel Barreiro-de Acosta, Juan E Dominguez-Munoz
No abstract text is available yet for this article.
May 17, 2017: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/28512287/levels-of-faecal-calprotectin-and-magnetic-resonance-enterocolonography-correlate-with-severity-of-small-bowel-crohn-s-disease-a-retrospective-cohort-study
#6
Lei Ye, Wei Chen, Bi-Qin Chen, Xing Lan, Shao-Dong Wang, Xiao-Chen Wu, Wei Huang, Fang-Yu Wang
Few studies have evaluated the usefulness of fecal calprotectin (FC) or magnetic resonance enterography (MRE) in diagnosing active Crohn's disease (CD) of the small bowel. In the study, we investigated the reliability of FC and MRE in assessing the activity of ileal CD and further explored the relationship between levels of FC and MRE scores. A total of 221 patients were diagnosed with ileal or ileo-colitis CD in our department between July 2012 and October 2016. The global magnetic resonance index of activity (MaRIA) correlated with the simple endoscopic score for CD (SES-CD) (r = 0...
May 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28511198/clinical-utility-of-fecal-calprotectin-monitoring-in-asymptomatic-patients-with-inflammatory-bowel-disease-a-systematic-review-and-practical-guide
#7
Anke Heida, K T Park, Patrick F van Rheenen
BACKGROUND: In asymptomatic patients with inflammatory bowel disease (IBD), "monitoring" involves repeated testing aimed at early recognition of disease exacerbation. We aimed to determine the usefulness of repeated fecal calprotectin (FC) measurements to predict IBD relapses by a systematic literature review. METHODS: An electronic search was performed in Medline, Embase, and Cochrane from inception to April 2016. Inclusion criteria were prospective studies that followed patients with IBD in remission at baseline and had at least 2 consecutive FC measurements with a test interval of 2 weeks to 6 months...
June 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28501098/alterations-in-intestinal-microbiota-relate-to-intestinal-failure-associated-liver-disease-and-central-line-infections
#8
Panliang Wang, Ying Wang, Lina Lu, Weihui Yan, Yijing Tao, Kejun Zhou, Jie Jia, Wei Cai
BACKGROUND: The gut microbiota plays a vital role in modulating the metabolic and immune functions of the intestines. We aimed to analyze the dysbiosis of microbiota in infants with short bowel syndrome (SBS) with different complications. PROCEDURE: We included 26 fecal samples from 18 infants with SBS during parenteral nutrition. The samples were categorized into three groups: asymptomatic, parenteral nutrition-associated liver disease (PNALD), and central line-associated bloodstream infection (CLABSI)...
May 3, 2017: Journal of Pediatric Surgery
https://www.readbyqxmd.com/read/28498159/fecal-calprotectin-is-not-affected-by-pregnancy-clinical-implications-for-the-management-of-pregnant-patients-with-inflammatory-bowel-disease
#9
Mette Julsgaard, Christian L Hvas, Richard B Gearry, Thea Vestergaard, Jan Fallingborg, Lise Svenningsen, Jens Kjeldsen, Miles P Sparrow, Signe Wildt, Jens Kelsen, Sally J Bell
BACKGROUND: Noninvasive biomarkers of inflammation for monitoring inflammatory bowel disease (IBD) are important in pregnancy. Clinical and laboratory markers are often affected by the physiological adaption that occurs during pregnancy, although, few, if any, data exist on fecal calprotectin (FC). We investigated FC concentrations in pregnant controls and IBD women, and whether FC correlated with physician global assessment (PGA), C-reactive protein (CRP), and Harvey-Bradshaw Index (HBI)/Simple Clinical Colitis Activity Index (SCCAI) before and after pregnancy, as well as during each trimester...
May 11, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28491862/comparison-of-fecal-calprotectin-methods-for-predicting-relapse-of-pediatric-inflammatory-bowel-disease
#10
Saranya Kittanakom, Md Sharif Shajib, Kristine Garvie, Joceline Turner, Dan Brooks, Sufian Odeh, Robert Issenman, V Tony Chetty, Joseph Macri, Waliul I Khan
Background. Pediatric inflammatory bowel disease (IBD) is on the rise worldwide. Endoscopies are necessary for IBD assessment but are invasive, expensive, and inconvenient. Recently, fecal calprotectin (FCal) was proposed as a noninvasive and specific marker of gut inflammation. We evaluated the analytical performance of three FCal assays and their clinical performance in predicting relapse in pediatric IBD. Methods. This study used 40 pediatric IBD and 40 random non-IBD patients' fecal samples. Two automated ELISAs (Bühlmann and PhiCal® Calprotectin-EIA) and an EliA (Phadia 250 EliA-Calprotectin) were used to evaluate the analytical performance...
2017: Canadian Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28454097/upregulation-of-calprotectin-in-mild-ige-mediated-ovalbumin-hypersensitivity
#11
Qingling Zhu, Feng Li, Junli Wang, Jingqiu Ma, Xiaoyang Sheng
Calprotectin, also known as S100A8/A9, has been linked to gut inflammation caused by IgE-mediated food hypersensitivities, but the pathophysiologic abnormalities it causes remain to be determined. We created a mild food hypersensitivity model through oral gavage of ovalbumin in Norway brown rats without using immune adjuvant. Changes in the levels of calprotectin and inflammation-associated cytokines were then observed over time. We found that fecal calprotectin as well as jejunal and liver TLR4, TNF-α, NF-κB, IL-1β, and IL-6 were upregulated in hypersensitive rats...
April 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28447072/a-randomized-trial-of-the-effects-of-the-no-carrageenan-diet-on-ulcerative-colitis-disease-activity
#12
Sumit Bhattacharyya, Theresa Shumard, Hui Xie, Amar Dodda, Krista A Varady, Leo Feferman, Allan G Halline, Jay L Goldstein, Stephen B Hanauer, Joanne K Tobacman
BACKGROUND: Carrageenan is a very common food additive in Western diets, but predictably causes inflammation in thousands of cell-based and animal experiments. OBJECTIVE: To assess the impact of carrageenan exposure on the interval to relapse in patients with ulcerative colitis in remission. METHODS: A randomized, double-blind, placebo-controlled, multicenter, clinical trial was conducted to assess if patients with ulcerative colitis in remission would have a longer interval to relapse if they followed a diet with no carrageenan...
March 31, 2017: Nutrition and Healthy Aging
https://www.readbyqxmd.com/read/28442839/the-place-of-calprotectin-lactoferrin-and-high-mobility-group-box-1-protein-on-diagnosis-of-acute-appendicitis-with-children
#13
Sevgi Buyukbese Sarsu, Ayse Binnur Erbagci, Hasan Ulusal, Suleyman Cuneyt Karakus, Özlem Gümüstekin Bulbul
The purpose of this study is to investigate the role of serum calprotectin (CP), lactoferrin (LF), and high-mobility group protein B1 (HMGB-1) levels and fecal CP and LF levels in differential diagnosis of acute uncomplicated appendicitis from other causes of abdominal pain and further from complicated appendicitis. Totally, 120 children were included grouped into 4 as: healthy controls, patients with right lower quadrant pain with other than surgical causes, patients with uncomplicated appendicitis, and patients with complicated appendicitis...
April 2017: Indian Journal of Surgery
https://www.readbyqxmd.com/read/28442699/does-the-rapid-fecal-calprotectin-test-equally-predict-mucosal-inflammation-in-both-ulcerative-colitis-uc-and-crohn-s-disease-cd-a-prospective-analysis-of-an-ibd-cohort
#14
Andrzej Moniuszko, Stanisław Głuszek, Grażyna Rydzewska
INTRODUCTION    Fecal calprotectin (FC) is a well-established biomarker of intestinal inflammation in CD and UC. However, standard laboratory methods are time consuming and not always useful in clinical practice.  OBJECTIVES    We analyzed the efficacy of a rapid bedside FC test to detect disease flares in a hospital setting. We also assessed the influence of disease location on diagnostic accuracy. PATIENTS AND METHODS    140 patients were prospectively enrolled in the study (46 UC, 94 CD). FC was measured both by ELISA and by the rapid Quantum Blue® test...
April 26, 2017: Polish Archives of Internal Medicine
https://www.readbyqxmd.com/read/28426458/anti-tnf%C3%AE-treatment-after-surgical-resection-for-crohn-s-disease-is-effective-despite-previous-pharmacodynamic-failure
#15
Amit Assa, Jiri Bronsky, Kaija-Leena Kolho, Kristyna Zarubova, Tim de Meij, Oren Ledder, Margaret Sladek, Stephanie van Biervliet, Caterina Strisciuglio, Raanan Shamir
BACKGROUND: The outcome of patients with Crohn's disease who failed anti-tumor necrosis factor alpha (anti-TNFα) therapy despite adequate serum drug levels (pharmacodynamic failure) is unclear. We aimed to assess such pediatric patients who underwent intestinal resection and were re-treated with the same anti-TNFα agent postoperatively. METHODS: Pediatric patients with Crohn's disease who underwent intestinal resection and were treated with anti-TNFα agents postoperatively were assessed retrospectively...
May 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28423962/the-utility-of-fecal-calprotectin-in-predicting-the-need-for-escalation-of-therapy-in-inflammatory-bowel-disease
#16
Lukasz Kwapisz, Jamie Gregor, Nilesh Chande, Brian Yan, Terry Ponich, Mahmoud Mosli
BACKGROUND AND AIMS: Fecal calprotectin is an important biomarker used in the evaluation of inflammatory bowel disease. It has proven to be an effective tool in initial screening as well monitoring response to therapy. The aim of this study is to examine the utility of fecal calprotectin both as a predictor for the escalation of therapy in established inflammatory bowel disease and as a predictor of de novo diagnosis. METHODS: Patients with signs and symptoms concerning for inflammatory bowel disease presenting to outpatient clinics were recruited to provide fecal calprotectin stool samples prior to endoscopic evaluation...
April 20, 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/28421251/defining-the-ultrasound-longitudinal-natural-history-of-newly-diagnosed-pediatric-small-bowel-crohn-disease-treated-with-infliximab-and-infliximab-azathioprine-combination-therapy
#17
Jonathan R Dillman, Soudabeh Fazeli Dehkordy, Ethan A Smith, Michael A DiPietro, Ramon Sanchez, Vera DeMatos-Maillard, Jeremy Adler, Bin Zhang, Andrew T Trout
BACKGROUND: Little is known about changes in the imaging appearances of the bowel and mesentery over time in either pediatric or adult patients with newly diagnosed small bowel Crohn disease treated with anti-tumor necrosis factor-alpha (anti-TNF-α) therapy. OBJECTIVE: To define how bowel ultrasound findings change over time and correlate with laboratory inflammatory markers in children who have been newly diagnosed with pediatric small bowel Crohn disease and treated with infliximab...
April 18, 2017: Pediatric Radiology
https://www.readbyqxmd.com/read/28420947/the-use-of-fecal-calprotectin-in-inflammatory-bowel-disease
#18
Ingvar Bjarnason
No abstract text is available yet for this article.
January 2017: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28416415/age-dependent-variation-of-fecal-calprotectin-in-cystic-fibrosis-and-healthy-children
#19
Millie Garg, Steven T Leach, Michael J Coffey, Tamarah Katz, Roxanne Strachan, Tamara Pang, Bronwen Needham, Kei Lui, Fathalla Ali, Andrew S Day, Laura Appleton, Vesal Moeeni, Adam Jaffe, Chee Y Ooi
BACKGROUND: Fecal calprotectin may be used as a non-invasive method to assess the effect of novel therapies on the gut in cystic fibrosis (CF). METHOD: Stools from CF patients and healthy controls (HC) (0-10years old) were prospectively collected for evaluation of temporal trends. RESULTS: 130 CF samples (64 subjects) and 114 HC samples (101 subjects) were collected. Overall, fecal calprotectin levels were different in CF patients and HC from 0 to 10years (P=0...
April 14, 2017: Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society
https://www.readbyqxmd.com/read/28410341/effects-of-transient-and-persistent-anti-drug-antibodies-to-certolizumab-pegol-longitudinal-data-from-a-7-year-study-in-crohn-s-disease
#20
William J Sandborn, Douglas C Wolf, Gordana Kosutic, Gerry Parker, Stefan Schreiber, Scott D Lee, Bincy Abraham, Anita Afzali, Razvan I Arsenescu, Alexandra Gutierrez, Marshall Spearman, Jason Coarse, Brian G Feagan
BACKGROUND: Anti-drug antibodies (ADAbs) may decrease the efficacy of biologics and increase the risk of adverse events. A single positive test may not preclude further treatment because of variations in assays used, test timing, and patient variables. We evaluated the longitudinal patterns of immunogenicity during 7 years of antitumor necrosis factor-alpha drug certolizumab pegol (CZP) treatment for moderate-to-severe Crohn's disease. METHODS: PRECiSE 3 patients (n = 595) received open-label CZP 400 mg every 4 weeks up to 7 years...
April 13, 2017: Inflammatory Bowel Diseases
keyword
keyword
27773
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"